Product/Service

albucult®

Source: Novozymes Biopharma US Inc.
Derived from our proprietary S. cerevisiae yeast expression technology albucult* has been developed to deliver quality and unprecedented performance benefits in our customers' applications including drug and vaccine manufacture, device coating, IVF media and cell therapy applications.
Recombinant albumin for drug, vaccine and device manufacturing

Derived from our proprietary S. cerevisiae yeast expression technology albucult* has been developed to deliver quality and unprecedented performance benefits in our customers' applications including drug and vaccine manufacture, device coating, IVF media and cell therapy applications.

Key benefits

  • Animal-free
  • Secure supply in large volume quantities
  • cGMP for regulatory-compliance and consistency
  • Exceptional purity profile
  • Consistent quality can mean reduced lot testing or vendor auditing
  • Convenient liquid format.

Application areas

  • Drug manufacturing
    • Half-life extension of peptides
    • Drug targeting and delivery
    • Albumin micro- and nanoparticle-based drugs.
  • Medical devices
    • Coating
    • IVF and advanced cell therapy media ingredient.